These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date||2007-005204-40||A PHASE III STUDY OF VELCADE (BORTEZOMIB) DEXAMETHASONE (VD) VERSUS VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATI...||2009-07-02||bad-data|
|Not reported||2008-003486-58||Pharmacogenomic study to predict survival, best response and toxicity in newly diagnosed myeloma patients who are either 65 years of age or older treated with either a combination of melphalan-prednis...||2016-07-14||due-trials|
|Ongoing||2009-012359-91||Multicenter Phase II Study of Bendamustine, Velcade (Bortezomib) and Dexamethasone (BVD) in the treatment of elderly patients (> or =65 years) with multiple myeloma in 1st relapse or refractory to 1st...||not-yet-due|
|Listed as ongoing, but also has a completion date||2014-004781-15||Study of Daratumumab in Combination with Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects with Newly Diagnosed Multiple Myeloma||2018-06-06||bad-data|